More recently, the DESTINY-Breast02 confirmed the superiority of T-DXd over trastuzumab or lapatinib in combination capecitabine in patients with HER2-positive metastatic BC who had experienced treatment failure with T-DM1, with no additional safety concerns. The gene discussed is ERBB2; the disease is breast cancer.